Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Emerging strategies to preserve renal function Francois H; Jacquet A; Beaudreuil S; Seidowsky A; Hebibi H; Charpentier B; Durrbach AJ Nephrol 2011[Mar]; 24 (2): 133-41Although there has been tremendous improvement in managing chronic kidney disease (CKD) with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in the last 15 years, CKD still progresses. Therefore, new emerging strategies are needed. The gold standard still lies with optimum renin-angiotensin-aldosterone system blockade, although many questions remain about how this is best achieved, such as regarding the efficacy of combinations of ACE inhibitor and ARBs, supramaximal doses of ARBs alone and combinations of either ACE inhibitor or ARBs with direct renin inhibitors, antialdosterone agents. Other promising molecules currently being tested are endothelin receptor antagonists and glitazones. Also, the role of other current therapies being used during CKD, including statins, vitamin D and erythropoiesis-stimulating agents, will be discussed, as these may also exert nephroprotective effects.|Angiotensin Receptor Antagonists/therapeutic use[MESH]|Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]|Chronic Disease[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use[MESH]|Kidney Diseases/*drug therapy/physiopathology[MESH]|Kidney/*physiopathology[MESH]|Renin-Angiotensin System/*physiology[MESH]|Vitamin D/therapeutic use[MESH] |